On 26 May 2021, EU Medical Device Regulation (MDR) replaced the EU’s current Medical Device Directives and while the medical devices manufacturers have largely ensured compliance with the new regulation, this change will have an impact on development of documentation related to the medical devices, translation and regulatory cycles in the EU.
In literally every survey that we have ever conducted among our clients from the pharmaceutical and medical devices industries, accurate terminology has always been singled out as the primary concern in translation for these sectors. In this article, we will take a closer look at the reasons for this and how the translation technologies can help us address this issue and ensure accuracy of terminology.
We are happy to announce that Ciklopea, in its capacity as one of the leading providers of advanced language solutions for the life sciences sector, will exhibit at the forthcoming DIA Europe 2021 (virtual) event.
We are happy to announce that our CSO Mladen Stojak and our Business Development Representative Nancy Hähnel will be among the panelists at the NEXT Pharma Summit webinar Digital Asset Management in Localization Process and How to Do It Better? on 31 March 2021.
Patient-facing content includes all medical and pharmaceutical materials targeted at patients and end users who are not necessarily familiar with expert terminology and procedures.
Depending on their purpose, these materials may cover a wide range of topics, from legal information to instructions for use of medical devices, and all of this must be conveyed in a clear and unambiguous manner to make the information understandable to the non-expert target audiences.
We are happy to announce that our new microsite developed to provide detailed information on language solutions for the medical and pharmaceutical industries has been launched.
That dreadful phrase bad translation has two distinct meanings – first, there is the obvious one, a text (or any other material) replete with errors in meaning, style, grammar and orthography and second, the more serious one, including delayed and cancelled product launches, loss of time, resources and energy and, most dreadful of them all, negative representation on a foreign market, which is also the price of a bad translation.
How to prevent it?
The amount of textual materials used before, during and after clinical research is often massive as they include a wide range of documents composed by healthcare professionals, legal and financial experts and patients. If any of these documents needs to be updated or changed for any reason, amending and updating the translated versions may be difficult and time-consuming.
Luckily, there are processes and technologies designed to make these actions painless.
Transcreation is most definitely not one of the things that spring to mind when we talk about the medical translation or localization of pharmaceutical materials. With all the seriousness of study protocols, summaries of product characteristics and correspondences with the regulatory bodies, we tend to forget that medical and pharmaceutical companies also need marketing solutions to propel their business and reach their customers and clients.
We help life sciences, IT & software and technology and manufacturing industries communicate their message to the foreign markets and secure a positive presence on a global scale. Want to join our team? Continue reading… As a Sales Representative, you will be part of the team enabling Ciklopea to strengthen its position as a leader […]
The task of language professionals is essentially the same across industries and can always be summarized as helping companies and organizations communicate their messages to the target audiences, partners and clients. In this article we take a look at what medical translators need to know to make this communication possible in the vast and the diverse world of life sciences.
Pharmaceutical and medical industries are the two biggest players in the life sciences sector who frequently launch and sell their products on the global markets. Of course, to do so, they need to approach each of these markets with the utmost care. We are all their customers and we all have different healthcare needs and desires.
Companies in the life sciences industry invest huge amounts into keeping their businesses growing, especially when moving into a new market. Behind the scenes lots of work goes into keeping these companies afloat, and it couldn’t be done without localization.
The massive amount of life sciences texts being translated to almost every written language of the world every day is essentially an active exchange of information on the cutting-edge life sciences products, procedures and development that are constantly widening the lexical stock of the target languages and thus make a valuable contribution to the scientific arenas of the target territories.
When we talk about the life sciences in the context of language industry, it is, for the most part, about the translation and localization of medical and pharmaceutical content.
Ciklopea
Mladen Stojak